Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) First Quarter 2025 Results
Key Financial Results
- Revenue: CN¥179.9m (up 22% from 1Q 2024).
- Net income: CN¥2.67m (up 14% from 1Q 2024).
- Profit margin: 1.5% (down from 1.6% in 1Q 2024). The decrease in margin was driven by higher expenses.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's share price is broadly unchanged from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 2 warning signs for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd you should be aware of, and 1 of them is concerning.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.